QIAGEN’s QuantiFERON-TB Gold Plus Shows Cost-Effectiveness Compared With TST in a Newly Published Study in People With HIV

9 February 2026

QIAGEN press release

A peer-reviewed health-economic analysis evaluated TB infection (TBI) screening strategies among people living with HIV in Thailand. QuantiFERON-TB Gold Plus reduced the modeled lifetime risk of progression to active TB among individuals with TBI by approximately 41% compared with tuberculin skin test (TST).

The study was conducted to support evidence-based decision making in Thailand and to help policymakers in low- and middle-income countries evaluate screening options for detecting TB infection.

The analysis modeled one-time TBI screening in adults living with HIV and projected lifetime costs and health outcomes based on Thai epidemiological and cost data.

Read the full press release here.

Source: QIAGEN